famotidine has been researched along with Morbid Obesity in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine and ranitidine were compared as agents for the prevention of acid aspiration syndrome in 32 morbidly obese patients undergoing vertical banded gastroplasty." | 5.07 | Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine. ( Canet, J; Melero, A; Vallès, J; Vidal, F; Vila, P, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vila, P | 1 |
| Vallès, J | 1 |
| Canet, J | 1 |
| Melero, A | 1 |
| Vidal, F | 1 |
1 trial available for famotidine and Morbid Obesity
| Article | Year |
|---|---|
Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.
Topics: Adult; Famotidine; Female; Gastric Acidity Determination; Gastric Juice; Gastroplasty; Humans; Male; | 1991 |